Abstract The apolipoprotein E4 allele (APOE4) contributes to Alzheimer's disease (AD) risk and APOE2 is protective, but the relevant cellular mechanisms are unknown. We have used flow cytometry analysis to measure apolipoprotein E (apoE) and amyloid beta peptide (Ab) levels in large populations of synaptic terminals from AD and aged cognitively normal controls, and demonstrate that modest but significant increases in soluble apoE levels accompany elevated Ab in AD cortical synapses and in an APP/PS1 rat model of AD. Dual labeling experiments document co-localization of apoE and Ab in individual synapses with concentration of Ab in a small population of apoE-positive synapses in both AD and controls. Consistent with a clearance role, the apoE level was higher in Ab-positive synapses in control cases. In aged targeted replacement mice expressing human apoE, apoE2/4 synaptic terminals demonstrated the highest level of apoE and the lowest level of Ab compared to apoE3/3 and apoE4/4 lines. In apoE2/4 terminals, the pattern of immunolabeling for apoE and Ab closely resembled the pattern in human control cases, and elevated apoE was accompanied by elevated free cholesterol in apoE2/4 synaptic terminals. These results are consistent with a role for APOE in Ab clearance in AD synapses, and suggest that optimal lipidation of apoE2 compared to E3 and E4 makes an important contribution to Ab clearance and synaptic function.
Introduction
Many environmental risk/lifestyle factors and susceptibility genes for Alzheimer's disease (AD) have been reported. However, for sporadic or late-onset Alzheimer's disease, which represents the vast majority of cases, apolipoprotein E (APOE) remains the strongest genetic risk factor, with 60-80% of AD cases having at least one apoE4 allele (for review see [31, 37] ). Like other apolipoproteins, apoE is a cholesterol chaperone, and a ligand for members of the low-density lipoprotein receptor (LDLR) family. The human gene exists in three alleles, (E2, E3 and E4); while APOE4 confers risk for AD [9] , APOE2 is protective [8] .
In the brain, most apoE is produced by astrocytes, which are thought to deliver cholesterol and other lipids to neurons via receptor-mediated endocytosis. In normal brain, APOE4 is associated with reduced pre-and postsynaptic proteins, and APOE2 with increases in a key post-synaptic protein, PSD-95 [40] . In addition to cholesterol transport, a number of isoform-dependent functions have been identified for apoE in vitro and in vivo. For example, APOE4 has been linked to accumulation of intraneuronal amyloid beta protein (Ab; [7] ) and to capillary cerebral amyloid angiopathy [65] ; however, the mechanism(s) by which APOE4 confers risk for AD remain unclear.
The three isoforms of apoE differ at two amino acids (position 112 and 158), which alter lipid association and receptor binding of apoE. The major apoE receptors in brain are the LDLR and the LDL-related protein (LRP1).
A strong body of evidence shows that apoE also binds tightly with the Ab protein [35, 36, 49] , and this interaction is widely hypothesized to influence Ab deposition and dementia progression in AD. For example, increased neuritic plaques in AD and fibrillar Ab burden are associated with APOE4 dosage [53, 66] . In vitro experiments show that lipidated apoE4 forms less SDS-stable apoE/Ab complex compared to apoE2 and apoE3 [35, 76] , and our earlier work has demonstrated that complex formation with apoE3 enhances uptake of soluble but not aggregated Ab into synaptosomes [18] . The impaired ability of apoE4 to bind Ab has suggested a hypothesis in which the apoE4 allele reduces Ab clearance in the brain of AD patients by reducing receptor-mediated uptake and cellular metabolism of the apoE/Ab complex. Isoform-related differences in receptor-mediated uptake have also been shown to occur across the endothelium into the blood, with apoE2-and apoE3-containing Ab complexes cleared from the brain at a faster rate than apoE4/Ab complexes [10] . Recent evidence also suggests that complex formation with apoE4 may reduce peripheral Ab clearance [3, 26] . Despite a large body of in vitro evidence, the cellular location and function of neuronal apoE/Ab complexes is not clear.
Synaptic dysfunction and loss are thought to be the earliest correlates of cognitive dysfunction, and a large body of evidence indicates an important role for apoE in synaptic integrity and plasticity. For example, apoE is up-regulated in rodents after neuronal injury [74] , and human apoE4 target replacement (TR) mice display impaired LTP and decreased dendritic spine density [28] . A role for apoE in plasticity and repair is supported by evidence that APOE4 carriers have poorer outcomes in head injury and stroke [42] , as well as higher rates of other neurologic disorders including tauopathies and PD [30, 45] . Based on the evidence linking synaptic plasticity to apoE, and the production of brain apoE by astrocytes that envelope and maintain synapses [67] , we hypothesized altered apoE level in AD cortical synapses. We also tested the hypothesis that apoE and Ab are colocalized, and report here that apoE level is modestly increased in AD compared to control, and that Ab is concentrated in a small population of apoE-positive synapses in both AD cortex and in TR mice expressing human APOE isoforms. Mice with APOE2 allele demonstrated the highest level of synaptic apoE and the lowest level of synaptic Ab, and these changes in the synapse were accompanied by elevated free cholesterol.
Methods

Materials
The monoclonal anti-Ab antibody 10G4 has been described previously [43] . Polystyrene microsphere size standards were purchased from Polysciences, Inc. (Warrington, PA, USA). Zenon mouse IgG Labeling kits for dual labeling were purchased from Molecular Probes (Eugene, OR, USA), and rhodamine-conjugated anti-mouse antibody from Chemicon (San Diego, CA, USA). The following monoclonal antibodies were purchased: anti-SNAP-25 (Sternberger Monoclonals Inc., Lutherville, MD, USA), mouse IgG1 Isotype control (BD Pharmingen, San Diego CA), apoE 2E1 (anti-human, Roche Diagnostics, Mannheim, Germany), and apoE E6D7 (directed against N-terminal human apoE, Abcam, Cambridge, MA, USA). Filipin and biotinylated Cholera Toxin subunit B were purchased from Sigma (St. Louis, MO, USA).
Human brain specimens
Samples of parietal (A39) cortex were obtained from the Alzheimer's Disease Centers at USC, UCLA, and UC Irvine on the day of autopsy. Immediately upon receipt, samples (*0.3-5 g) were minced in 0.32 M sucrose and slowly frozen for cryopreservation, then stored at -70°C until homogenization. The mean postmortem interval for AD cases was 6.7 h, and for normal and control cases were 8.6 h. Controls included aged cognitively normal controls and neurological control cases with spinocerebellar ataxia and other non-Alzheimer's disease conditions. Complete case information is presented in Table 1 .
Animals
ApoE TR mice
Human APOE genomic fragments were used to replace the mouse apoE gene via homologous recombination. All three lines of apoE TR mice contain chimeric genes consisting of mouse 5 0 regulatory sequences continuous with mouse exon 1 (non-coding) followed by human exons (and introns) 2-4 [62] . Thus, all three lines of apoE TR mice regulate gene expression in the same fashion. Mice have been backcrossed to C57Bl6/J mice 8 times and are therefore 99.6% C57Bl6/J. Animals were genotyped using an allele-specific PCR approach based on [23] . All mice were maintained on a normal chow diet and handled under protocols approved by the Duke Institutional Animal Care and Use Committee. Experiments were performed on 18-month-old male animals that were homozygous apoE 3/3, apoE 4/4 or heterozygous 2/4 mice. Rodent samples were cryopreserved as described above immediately after killing.
APP/PS1 transgenic rat
The transgenic APP/PS1 rats overexpress two human APP mutations (K670N/M671L and V717F) and one PS1 mutation (M146V). By 19-20 months of age, extensive amyloid plaque deposition is seen in hippocampal and cortical regions. The neuropathological characterization of these animals has previously been described in detail [16] .
P-2 preparation
The P-2 (crude synaptosome) fraction was prepared as described previously [18] ; briefly, tissue was homogenized in ice-cold buffer (0.32 M sucrose, 10 mM TRIS pH 7.5, plus protease inhibitors: pepstatin (4 lg/ml), aprotinin (5 lg/ml), trypsin inhibitor (20 lg/ml), EDTA (2 mM), EGTA (2 mM), PMSF (0.2 mM), Leu-peptin (4 lg/ml). The homogenate was first centrifuged at 1000g for 10 min; the resulting supernatant was centrifuged at 10,000g for 20 min to obtain the crude synaptosomal pellet. Aliquots of P-2 are routinely cryopreserved in 0.32 M sucrose and banked at -70°C until the day of the experiment.
Immunolabeling of P-2 fraction P-2 aliquots were immunolabeled for flow cytometry analysis according to a method for staining of intracellular antigens [55] . Pellets were fixed in 0.25% buffered paraformaldehyde (1 h, 4°C) and permeabilized in 0.2% Tween20/PBS (15 min, 37°C). Antibodies were labeled directly with Alexa Fluor 488 or 647 reagents according to kit directions. This mixture was added to P-2 aliquots and incubated at RT for 30 min. Pellets were washed twice with 1 ml 0.2% Tween20/PBS, resuspended in PBS buffer (0.75 ml) for flow cytometry analysis. The synaptosomal pellet was dispersed for all washes and for incubations with fixative, detergent, and antibody, then collected by centrifugation (1,310g at 4°C). ApoE ELISA ApoE levels were measures in P-2 samples using a sandwich ELISA using the protocol of Sullivan et al. [59] . Briefly, P-2 homogenate samples (20 lg protein) were loaded into a 96-well plate coated with an anti-apoE antibody (goat anti-human apoE; 1-200 dilution; Millipore, San Francisco, CA, USA). Following overnight incubation at 4°C, the samples were removed and the plate washed thrice with PBS-T (19 PBS, pH 7.4, 0.05% tween-20 and 0.4% glycine) prior to incubation with a biotinylated antiapoE antibody (goat anti-human apoE; 1:5,000; Meridian Life Science, Saco, ME, USA) for 1 h at room temperature. The plates were then washed again thrice with PBS-T and incubated with streptavidin-HRP for an additional 1 h at room temperature. The immunocomplex was reacted with TMB substrate and detected using a Versamax microplate reader (Molecular Devices, Sunnyvale, CA, USA). Levels of apoE were normalized to a standard curve generated using recombinant human apoE (Meridian Life Science, Saco, ME, USA).
Confocal microscopy
Crude P-2 aliquots were immunolabeled as described above and washed, then dispersed with a pipette and spread on slides. Slides were dried, coverslipped with Prolong Antifade (Molecular Probes, Eugene, OR, USA), and stored at 4°C. The Alexa 647 fluor usually used to label SNAP-25 was not compatible with the filter system on the microscope; therefore, samples were first incubated with 488-labeled 10G4 antibody and then anti-SNAP-25 antibody (1:1,000), followed by secondary antibody (rhodamine-conjugated anti-mouse, 1:200). Confocal fluorescence and differential interference contrast images of synaptosomes and plastic bead standards were taken using a 1009/1.4 Planapo objective lens on a Leica TCS-SP Confocal Inverted Microscope (Heidelberg, Germany) equipped with argon (488 nm excitation: blue) and heliumneon (633 nm excitation: red).
Statistics
Student's t tests were calculated using the Vassarstat interactive statistical website (http://faculty.vassar.edu/lowry/ VassarStats.html; Richard Lowry, Poughkeepsie, NY, USA).
Results
Synaptic terminal ApoE is elevated in AD cortex and in a transgenic rat model of AD
Previous work has demonstrated elevated Ab in cortical regions early in AD [48] , and we have previously demonstrated synapse-associated pathology including Ab oligomers and p-tau, reduced PSD-95, and dilated presynaptic terminals in multiple regions of AD cortex [14, 20, 21, 58] . The present experiments used synaptosomes prepared from crypreserved, short postmortem interval AD samples with clinical and histopathological confirmation of disease in order to measure apoE and Ab. Synaptosomes are formed as membranes instantaneously reseal when fresh tissue is gently homogenized in isotonic sucrose. Synaptosomes contain calcium and the presynaptic exocytotic apparatus, along with attached postsynaptic structures [13] , and the preparation has been widely used to study neurotransmitter regulation and release. Flow cytometry analysis of synaptosomes permits focus on a large and highly pure population (3,000-5,000 analyzed/case) of human synaptic terminals. Using an analysis gate including only particles between 0.50 and 1.5 l in size, the analysis is focused on a synaptosome population that is *95% pure; in comparison, gradientpurified synaptosomes are *80% pure [19, 72] . Figure 1 illustrates flow cytometry analysis for representative samples, with fluorescence plotted against the forward scatter parameter, which is proportional to particle size. The rectangular analysis gate is drawn to include only particles *1 micron and to include only immunolabeling above background. Ab fluorescence is plotted against the forward scatter parameter, which is proportional to particle size. Background labeling was determined in the presence of an isotype-specific IgG control (Fig. 1a) , and SNAP-25, an abundant presynaptic docking protein, was used as a positive control (Fig. 1b) . As previously reported, [14, 20, 21] , little Ab is detected in synapses from cognitively normal aged control cases (Fig. 1c ), but marked synaptic Ab accumulation is observed in AD parietal cortex, with *65% of terminals immunolabeled for Ab (Fig. 1d) . We have recently shown that the N-terminal epitope of the 10G4 antibody resembles 6E10 but more prominently labels Ab42 monomer, multiple oligomers and aggregates in synaptosomes with a pattern distinct from an N-terminal APP antibody [58] . Figure 1e , f illustrates the generally low level of apoE-associated immunofluorescence measured with flow cytometry analysis for AD parietal cortex synaptosomes; however, the apoE-positive fraction in synaptosomes is larger in the AD case (Fig. 1f) compared to a normal case (Fig. 1e) . Case information for all human samples is presented in Table 1 ; control comparisons include neurologic controls (Pick's disease, hippocampal sclerosis, and spinocerebellar degeneration) in addition to cognitively normal aged controls. Neurologic controls were included to determine the degree to which synaptic changes are specific for AD. Moreover, a large fraction of probable AD and MCI diagnoses are mixed dementia on neuropathological exam [56] . Flow cytometry was used to quantify synaptic apoE levels in a larger sample; Fig. 2a confirms the larger apoEpositive fraction in AD compared to normal synaptosomes, suggesting increased synaptic apoE associated with or in response to synaptic pathology. A similar modest but significant increase in synaptic apoE was measured by flow cytometry in hippocampal synaptosomes from 20-month old APP/PS1 transgenic rats ( [16] ; Fig. 2b ). Similar increases were observed when PBS-soluble apoE was measured by ELISA using synaptosome-enriched fractions [58] from cortex of human (n = 5 each for AD and control, Fig. 2c ) and aged APP/PS1 rats. Ab is concentrated in a small population of apoE-positive synapses with more Ab/synapse in AD cases
To test the hypothesis that apoE is increased in parietal cortex synapses with Ab pathology, synaptosomes were dual labeled for apoE and for Ab; flow cytometry data were collected (5,000 particles/sample) for apoE-positive synaptosomes as shown in the representative dot plot in Fig. 3a . In AD cases, apoE-positive synaptosomes were highly labeled for Ab as seen in the representative dot plots in Fig. 3b , c which illustrate the flow cytometry analysis for the same dual-labeled AD sample shown in Fig. 3a .
Additional flow cytometry controls and representative dual labeling for a normal case are shown in Supplemental Figure 1 . In Fig. 3b , the fluorescence associated with Ab is plotted against apoE fluorescence, and dual-labeled synaptosomes are in the upper right quadrant. Figure 3c shows Ab fluorescence in the apoE-positives as a function of size (forward scatter). When the size of the positive fraction is plotted (Fig. 3d) , relatively high levels of Ab in apoEpositives were observed in both normal (47 ± 10.9%) and AD cases (62 ± 3.5% positive), and Ab was markedly increased in apoE-positive compared to apoE-negative synapses for both AD (p \ 0.0001) and control cases (p \ 0.01). These results indicate that much of the total Ab is concentrated within the small population of apoEcontaining synapses.
Flow cytometry quantifies brightness of fluorescence in addition to size of positive fraction; when the brightness of fluorescence (relative fluorescence units, RFU) is plotted (Fig. 3e) , a large difference is observed between the Ab fluorescence associated with the apoE-positive terminals in normal (22.13 ± 2.6 RFU) compared to AD cases (105.64 ± 20 RFU). An increase in brightness when the size of the positive fraction is not significantly different translates to an increased level of Ab per apoE-containing synapse in AD cortex, indicating much more Ab/apoEpositive synaptic terminal in AD cortex. Similar to results for the percent positive parameter, Ab level was higher in apoE-positive compared to apoE-negative terminals for control (p \ 0.03) and AD cases (p \ 0.004), confirming concentration of Ab in apoE-positive synaptosomes.
In Ab-positive synapses, apoE level is higher for control cases
The converse analytic strategy was also performed, with collection and analysis of 5,000 Ab-positive synapses dual labeled for apoE. Figure 3f demonstrates that, in Ab-positive terminals, apoE is higher in non-AD control cases (50.29 vs. 35.84 RFU, p \ 0.005). The increase in apoE per Ab-bearing synapse in aged control cases is consistent with a role for the level of synaptic apoE in Ab clearance. Taken together, dual-labeling results suggest that apoE and Ab are concentrated in a relatively small fraction of apoE-positive synaptic terminals in both AD and normal cases. This result suggests that each is targeted to the same synaptic terminals, possibly via direct apoE/Ab binding and receptor-mediated entry into synaptic terminals, which has been shown to occur in vitro [35, 44] and in vivo [49] . Confirmation of apoE/Ab colocalization by confocal analysis in representative AD synaptosomes is illustrated in Fig. 4 .
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Synaptic Ab and apoE in TR mice expressing human APOE
To examine for isoform-dependent apoE effects, synaptosomes were prepared from cryopreserved cortex samples from 18-month-old apoE TR mice expressing human apoE 2/4, 3/3 and 4/4 [32, 61, 62] . ApoE TR mice are a wellcharacterized in vivo model for the study of human APOE; each apoE TR line expresses human apoE under control of mouse regulatory elements, and TRE4 mice display reduced plasma, CSF, and brain levels of apoE compared to 3/3 and 2/2 [1, 59] . Heterozygous apoE2/4 mice were used because type III hyperlipoproteinemia has been demonstrated in homozygous animals [63] . Synaptosomes were dual labeled for apoE and Ab and analyzed by flow cytometry as described above for human cortex samples. A majority of synaptic terminals (*50-80%, 5,000 events/ sample) demonstrate widespread low levels of synaptic Ab immunoreactivity in aged TR mice (Fig. 5) , despite the absence of AD-related mutations. This observation is consistent with previous observation of parenchymal (Fig. 1) , but resembles the intermediate levels of synaptic Ab seen in some cognitively normal aged controls and in PD cases [58] .
Synaptic apoE and Ab levels in apoE2 TR mice resemble non-AD control cases
As in human synapses, apoE-positive synaptosomes were highly labeled for Ab as illustrated by the representative plots in Fig. 6a -c, which illustrate the flow cytometry analysis for the same dual-labeled apoE TR 3/3 sample. The fluorescence associated with Ab is plotted against apoE fluorescence in Fig. 6b , in which dual-labeled synaptosomes are in the upper right quadrant. Ab fluorescence in the apoE-positives as a function of size (forward scatter) is plotted in Fig. 6c . Similar to relatively low apoE levels measured by flow cytometry in human and APP/PS1 synaptosomes, the apoE-positive fraction was fairly small; the highest apoE-positive fraction was measured in apoE2/4 animals (16.0 ± 0.6), and the smallest positive fraction was in apoE4/4 animals (9.7 ± 1.0; p \ 0.05). In contrast to previous results showing reduced spine density in apo-ETR4 mice [12] , pre-synaptic (SNAP-25) and postsynaptic (PSD-95) were not reduced in aged 4/4 animals (data not shown). Also similar to the results above in AD and normal cases, relatively high levels of Ab in apoEpositives were observed in all three TR lines (*50-80% positive), and Ab levels were higher in apoE-positives compared to apoE-negatives for all three TR lines (p \ 0.001), consistent with targeting of apoE and Ab to the same small population of synapses. When the brightness of fluorescence is plotted (Fig. 6e) for the apoE TR lines, the Ab fluorescence associated with the apoE-positive terminals is much lower in apoE2/4 compared to apoE3/3 and 4/4 animals. As for human results, the Ab RFU was markedly higher in apoE-positive compared to apoE-negative terminals for 3/3 and 4/4 TR lines ( Table 1 .
Synaptic apoE and free cholesterol levels are elevated in the presence of ApoE2
Again resembling AD versus control results, when the converse analytic strategy was performed with collection and analysis of Ab-positive synapses dual labeled for apoE, the apoE level/Ab-containing synapse was highest in TR 2/4 compared to 4/4 mice (26.5 vs. 15.8; p \ 0.003).
Reasoning that apoE changes may alter synaptic lipids, we next labeled aged TR synaptosomes with filipin, a fluorescent polyene antibiotic that binds unesterified cholesterol [47] , and with cholera toxin B subunit to label GM1 gangliosides (GM1) for flow cytometry analysis (Supplemental Figure 2) . Gangliosides are membrane glycosphingolipids with a hydrophilic sialic acid moiety and a hydrophobic ceramide core; free cholesterol and GM1 are major component of lipid rafts and both play important roles in signaling and particularly for Ab interaction with membranes [73, 75] . Figure 6d shows that, in TR2/4 compared to 4/4 animals, ganglioside GM1 was 
Discussion
Interaction between apoE and Ab is well-documented in vitro, but little is understood about the cellular mechanisms by which APOE4 confers risk and APOE2 confers protection from AD. In both aged cognitive normals and AD cases, apoE and Ab are highly co-localized in a small population of apoE-positive synaptic terminals, consistent with uptake of an apoE/Ab complex, or targeting of apoE to Ab-positive synapses. Consistent with clearance of Ab, the Ab level per synaptic terminal is markedly lower in normal control cases compared to AD. Similarly, with respect to isoform, the lowest level of synaptic Ab and the highest level of apoE are associated with APOE2 in aged TR animals without cognitive deficits or pathology. Higher synaptic free cholesterol suggests that increased apoE lipidation in the presence of E2 delivers cholesterol to the synapse. Reduced levels of plasma apoE in E4 compared to E2 and E3 carriers have long been documented [68] ; moreover, a reduction in total plasma apoE and apoE4 has recently been demonstrated in AD versus controls and to correlate with AD PiB-PET pathology [17] . In TR mice expressing human apoE, reduced apoE has been shown in plasma, brain and CSF in E4 compared to E2 and E3 [52, 54, 59] , and this reduction is likewise seen in the PDAPP mouse model of AD when crossed with TR line expressing human apoE2, 3 and 4 [1] . The present results extend this finding to the synaptic compartment, where the earliest cognitive deficits are hypothesized to occur [57] , suggesting that soluble synaptic apoE level may make a direct contribution to synaptic dysfunction in E4 carriers. A modest degree of difference in isoform-dependent apoE protein levels was observed in the present results and has been consistently observed by others. This result is consistent with the extended time required for expression of the increased AD risk conferred by E4 and the protection conferred by E2.
Clearance rather than production deficits have been suggested to predominate in the majority of typical lateonset AD cases [2] , which is consistent with the results of a trial measuring human CSF Ab clearance and production in AD and control patients [46] . Also confirming the importance of clearance, the recent in vivo microdialysis experiments in PDAPP/TR mice showed longer Ab halflife in PDAPP/E4 mice compared to PDAPP/E3 and PDAPP E2 animals [6] . In the present results, consistent and significant reductions in synaptic Ab were seen only in the TR2/4 line, with no major E3 versus E4 differences; in fact the total Ab-positive fraction was modestly larger in 3/3 compared to 4/4 terminals (Fig. 5d) . This main effect of the E2 allele therefore likely follows from a positive effect on clearance mechanisms since Ab production is not altered in these animals. The sharp reduction of synaptic Ab in apoE2 terminals (compared to E3 and E4-positives; Fig. 5e ), greatly resembles the same comparison in aged normals versus AD (Fig. 3e) , and serves to illustrate the importance of Ab clearance processes in sporadic AD. This similarity of the apoE/Ab results in sporadic AD and aged TR mice also highlights the usefulness of aged TR mice for study of Ab clearance without confounding of excess or mutated Ab production. The lack of an E4 effect in the apoE TR animals may indicate that E4-dependent reduced apoE levels may be required for a period longer than the mouse lifespan. On the other hand, increased Ab production or Ab42/40 ratio may also be necessary for full expression of enhanced Ab deposition by E4. In apoE2 TR synapses, Ab and apoE are still co-localized but there is less Ab. In vitro work has shown that lipidated apoE forms an SDS-stable complex more abundant with apoE2 and E3 compared to E4, which led to an early hypothesis that complex formation between apoE and Ab facilitates clearance [35, 36] . On the other hand, in vivo results suggest that apoE4/Ab complex formation may affect binding to the low-density lipoprotein receptorrelated protein (LR) and slow clearance of Ab across the endothelium into the blood [3, 10] . Insoluble apoE/Ab complexes with a fibrillar structure have been extracted from AD brain [49] , and evidence also supports co-deposition of apoE with Ab in plaques in human disease, particularly in newly formed plaques [38, 50, 64] . In old 5xFAD mouse, both Ab42 and apoE extraction shifts from the detergent-soluble fraction to buffer-soluble and insoluble fractions, consistent with a shift from association with lipids (detergent soluble) to localization with Ab in deposits (insoluble) and with oligomers ( [77] ; buffer soluble). This extraction pattern suggests that apoE may form complexes with multiple Ab assembly states, which has been observed in vitro [44] . Along this line, our finding that the Ab level per terminal in AD is higher than in normals, despite similar-sized positive fractions (Fig. 3e) , is consistent with a model in which apoE associates with multimeric Ab assemblies that might be oligomers, aggregates or fibrils. Indeed, in vitro complex formation has used a molar ratio of apoE to Ab of that varies from 1:30 [44] to 1:100-200 [41, 71] . Alternatively, complex formation may not be required, and colocalization of Ab and apoE within a cellular compartment may be sufficient for E2-enhanced clearance.
In PDAPP/apoE TR lines, co-localization of apoE and Ab42 was significantly increased in E4 compared to E3 and E2 lines; nearly all apoE was associated with Ab in old PDAPP/E4 animals, with only 25% co-localization in PDAPP/E2 animals [1] . This is in contrast to the present experiments where a high degree of co-localization was seen in all three apoE TR lines (77-92%, Fig. 5d ). We also observed relatively high co-localization in both normal and AD samples, 47 and 62%, respectively (Fig. 3d) .
Co-localization was measured by Bales and colleagues at the light microscope level and therefore includes deposited Ab, while our flow cytometry analysis was focused on synaptic terminals in animals without pathology or deposits. Importantly, in both studies, the E2 allele was associated with the highest level of apoE and the lowest level of Ab. Both results are consistent with E2-mediated enhanced clearance of Ab, possibly via the formation of more apoE/Ab complex due to the E2-related increased apoE level, or more efficient clearance of a complex containing apoE2. Considered together with the dual-labeling results, the increased synaptic apoE level observed in AD cases would be expected to follow over time from less efficient synaptic clearance of apoE/Ab complex in E3 and E4 carriers, since apoE2 alleles are found in only 15% of the population and are rare in AD postmortem cases, while the E4 allele is overrepresented in human AD [5, 56] .
Our previous results have shown increased free cholesterol and ganglioside GM1 in Ab-positive synaptosomes in AD, and a large body of results has shown a reciprocal relationship between cholesterol and Ab production [37] . Therefore, we hypothesized that E4 would increase cholesterol, and the striking increase in free cholesterol by E2 was surprising. The contribution of apoE to brain cholesterol levels is not well understood; in general the total cholesterol levels are either unchanged or decreased in AD, likely due to the abundance of cholesterol-rich myelin in brain, and to the difficulty of measuring cholesterol in different cell populations and in different subcellular compartments. To date, our experiments measuring synaptic free cholesterol in AD versus control cases have shown variable results (not shown). It seems likely that these results in human postmortem samples are confounded by the intracellular and extracellular accumulation of Ab over the decades, and by overrepresentation of E3 and E4 alleles. However, the present results are consistent with a hypothesis that isoform-dependent lipidation status may be important in AB deposition and AD via the liver X-receptor (LXR)-ABCA1-APOE regulatory axis [33, 34] . The ATP-binding cassette transporter A1 (ABCA1) transfers cholesterol from cells to lipid-poor apoE, forming high-density lipoprotein (HDL) particles. Emphasizing the importance of apoE level and lipidation, ABCA1 deficiency reduces soluble apoE levels and lipidation, resulting in either unchanged or increased Ab levels in AD mouse models [22, 34, 69] . ABCA1 and apoE levels are induced by treatment with liver X-receptor agonists, which reduce amyloid deposition in APP/PS1 animals [11, 29] and also diminish high-fat diet-induced pathology and memory deficits in APP23 mice [15] . Particularly relevant to the present experiments, overexpression of ABCA1 in PDAPP mice reduced Ab deposition via increased lipidation of apoE [69] , and in vitro experiments have demonstrated more efficient Ab degradation by IDE in the presence of highly lipidated apoE [29] .
In the model system used, apoE TR mice expressing human APOE, apoE4 expression has been associated with synaptic and spatial memory deficits even in the absence of pathology [4, 70] , and E4-dependent deficits were attenuated in apoE2/4 mice [32] . Confirmation of our cholesterol results is provided by the observation that brain lathosterol, a cholesterol precursor and indicator for cholesterol synthesis, is increased in E2 compared to E4 animals in the same apoE TR model [27] . Therefore, the high level of synaptic free cholesterol observed in 2/4 animals is consistent with the previous evidence of increased apoE lipidation. The observed APOE-related changes in free cholesterol are also supported by a number of previous results; for example, alterations in lipid raft cholesterol have been shown with with age and genotype in synaptic plasma membranes [25] . The importance of cellular cholesterol pools is also supported by evidence of abnormal cholesterol accumulation in the setting of apoE deficiency and environmental stimulation [39] , and by evidence that reduction of cholesterol esters by inhibition of acylcoenzymeA:cholesterol acyltransferase (ACAT) reduces amyloid pathology in vivo [24] . In addition to enhanced Ab clearance, improved lipidation and higher synaptic free cholesterol may contribute to improved synaptic function in these animals.
In synaptic terminals, large isoform-related differences in lipidation level/synaptic cholesterol are accompanied by relatively small differences soluble apoE levels. However, the nature of APOE-dependent risk for AD, like the increased risk for atherosclerosis, and poor outcome in closed head injury and stroke, represent relatively small differences in risk that take years or decades for full expression, consistent with a minor shift in function. The observed changes in apoE level and Ab clearance pathways operating in or near synapses highlight the potential of diet and apoE-related therapeutics in AD protection. It will be important in the future studies to examine for isoform effects in human cases, and for apoE and Ab colocalization and levels in glial cells, particularly in the astrocyte processes that surround and nourish synapses.
